• Blindness prevention possible with lifestyle changes

    Timely lifestyle changes can protect people at high risk of age-related macular degeneration (AMD) from vision loss into old age. This is a key intermediate result of the European research project EYE-RISK.

  • A look at ethical problems in Virtual Reality

    Dr. Philipp Kellmeyer, a researcher at the Freiburg University Hospital (Germany), calls for more sensitive use of virtual realities in medicine and nursing.

  • Research team identifies early cellular disorder in Alzheimer's disease

    Overactive nerve cells in certain areas of the brain are considered an early symptom of Alzheimer's disease. For the first time, a team from the Munich Technical University (TUM) was able to elucidate the causes and mechanisms of this initial and important step.

  • Painkiller resistance in pancreatic diseases deciphered

    Severe and persistent pancreatic pain is difficult to treat because many painkillers do not work in this organ. In a recent study, a team has discovered the reason: A certain endogenous nerve messenger substance is present in the pancreas’ nerves in very high concentrations.

  • A look at the first blood test for celiac disease

    Researchers found that in people with celiac disease, following gluten ingestion, certain inflammatory molecules associated with clinical symptoms occur in the bloodstream. These recently discovered biomarkers are the basis for the blood test.

  • Metastatic castration-resistant prostate carcinoma: Positive results from Phase 3 study

    Therapy with olaparib prolonged PFS in severely pretreated patients with mCRPC and defective DNA repair mechanisms by approximately 4 months compared to enzalutamide or abiraterone therapy.

  • Defeating food allergies with gastrointestinal microbiota

    Food allergies can be caused by the absence of certain intestinal bacteria. Current study results show that the replacement of these intestinal bacteria could make a decisive contribution to the treatment of allergies.

  • Metastatic bladder cancer: Atezolizumab prolongs PFS in first-line therapy when added to chemotherapy

    The PD-L1 inhibitor atezolizumab, when added to chemotherapy, prolonged the progression-free survival of untreated patients with metastatic bladder cancer from 6.3 to 8.2 months compared to chemotherapy.

  • Metastatic breast cancer: CDK4/6 inhibitors prolong survival

    Additional treatment with abemaciclib or ribociclib may prolong survival in women with advanced hormone receptor-positive and HER-2-negative breast cancer.

  • Checkpoint inhibitors: Better response of MSI-H tumors and tumors with high TMB

    Tumors with mismatch repair deficiency (MMRD) or tumors with high tumor mutational burden (TMB) respond better to therapy with checkpoint inhibitors than tumors without these properties.

  • Early breast cancer: Prognostic markers and updates of TAILORx and KATHERINE data

    New data for prognostic markers in early breast cancer as well as further analyses of the Phase 3 studies TAILORx and KATHERINE were presented at the ESMO Congress 2019 in Barcelona.

  • Measuring blood pressure with a “selfie” video

    Could smartphones be used to measure blood pressure? Canadian and Chinese researchers are suggesting that the smartphone camera could be used to make it easier to check blood pressure.

  • Melanoma: Good results with neoadjuvant and adjuvant therapy

    A vast array of study results on melanoma were presented by Piotr Rutkowski, from the Maria Skłodowska-Curie Institute of Oncology, Warsaw, Poland, during a highlight session at the ESMO Congress 2019.

  • Sarcoma: New data on ripretinib, regorafenib, sunitinib and nivolumab

    Sarcomas are relatively rare tumors that can occur on the soft tissue or bone. New study data on their treatment was presented by Javier Martin-Broto, Virgen del Rocio University Hospital, Seville, Spain.

  • NSCLC: Nivolumab plus low-dose ipilimumab used for first line therapy

    Treatment with a combined immunotherapy of nivolumab plus low-dose ipilimumab prolonged overall survival compared to chemotherapy in previously untreated patients with advanced NSCLC regardless of PD-L1 expression of the tumor.

  • NSCLC: Osimertinib as first-line therapy improves overall survival

    First-line therapy with osimertinib significantly prolongs overall survival of patients with non-small-cell lung carcinoma (NSCLC) compared to older tyrosine kinase inhibitors. This was shown by the evaluation of survival data from the FLAURA study

  • PARP inhibitors: New standard in first-line therapy of ovarian cancer?

    Three new studies with the PARP inhibitors niraparib, olaparib and veliparib showed a significant reduction in the risk of progression in first-line therapy of women with ovarian cancer.

  • Checkpoint inhibition in head and neck tumors

    The results of a 2018 comparative study were as good for inhibitors as those achieved with aggressive chemotherapy. The use of these drugs is currently being tested in the so-called ADRISK study at 13 ENT clinics in Germany.

  • Antibodies fighting HPV16 can indicate early tumor risk

    Antibodies against the human papillomavirus (HPV) 16 can be detected up to 40 years before the diagnosis of a head and neck tumor. People with HPV16 antibodies also have a much higher risk of oropharyngeal tumors.

  • An artificial heart from the printer

    Researchers at Carnegie Mellon University, USA, have developed a technique to produce biological tissue from collagens using 3D printing. The new method is an important step on the way to printing a first functioning human heart.

  • 66 |
  • 67 |
  • 68 |
  • 69 |
  • 70 |
  • 71 |
  • 72 |
  • 73 |
  • 74 |
  • 75 |
  • 76 |